Published Technical Disclosure Archive

Synergistic FLT3 Cancer Treatment System

Publication ID: 24-11857546_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic FLT3 Cancer Treatment System,” Published Technical Disclosure No. 24-11857546_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857546_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,546.

Summary of the Inventive Concept

A comprehensive system integrating crenolanib with AI, IoT, blockchain, and nanomaterials to treat FLT3 mutated proliferative disorders, enhancing treatment outcomes and patient monitoring.

Background and Problem Solved

The original patent disclosed the use of crenolanib for treating FLT3 mutated proliferative disorders. However, it lacked a comprehensive system for personalized treatment, real-time monitoring, and secure data storage. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system.

Detailed Description of the Inventive Concept

The system comprises a crenolanib administration module, a patient monitoring module utilizing artificial intelligence to predict treatment outcomes, and a blockchain-based data storage module to securely store patient data. Additionally, the system may include a genomics analysis module using next-generation sequencing to identify FLT3 mutations, an IoT-based patient monitoring system to track treatment efficacy, and a nanomaterial-based delivery system to enhance bioavailability and target FLT3-positive cancer cells.

Novelty and Inventive Step

The new inventive concept combines crenolanib with AI, IoT, blockchain, and nanomaterials to create a synergistic system, which is not obvious from the original patent. The integration of these distinct technologies provides a non-obvious solution to the problem of personalized FLT3 cancer treatment.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different AI algorithms, IoT devices, blockchain platforms, or nanomaterials. Variations may include the integration of additional technologies, such as machine learning or gene editing, to further enhance treatment outcomes.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the area of personalized cancer treatment. The system may be marketed to healthcare providers, pharmaceutical companies, and research institutions, offering a comprehensive solution for FLT3 cancer treatment.

Field of Art

Oncology, pharmaceutical biotechnology, and targeted cancer therapeutics, with specialized expertise in tyrosine kinase inhibitors and personalized medicine technologies

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in molecular biology or pharmacology, understanding cancer genomics, drug delivery systems, and emerging digital health technologies

Obviousness Rationale

A person of ordinary skill would recognize that integrating digital technologies with targeted cancer therapeutics represents a predictable extension of existing personalized medicine approaches. The combination of crenolanib with AI, IoT, and nanomaterial delivery systems follows established patterns of technological convergence in precision oncology. These variations represent incremental improvements that would be obvious to a skilled practitioner seeking to optimize cancer treatment monitoring and drug delivery.

Obvious Combinations & Variations

Source Patent Element
Method for treating FLT3 mutated proliferative disorders using crenolanib
PTD Variation
Adding AI-powered predictive analytics for treatment outcome monitoring
Obviousness Reasoning
Integrating machine learning with medical treatment is a known technique in precision medicine, representing a predictable application of existing digital health technologies
Source Patent Element
Pharmaceutical composition of crenolanib for cancer treatment
PTD Variation
Incorporating nanomaterial-based delivery systems to enhance bioavailability
Obviousness Reasoning
Nanotechnology-enhanced drug delivery is a well-established approach in pharmaceutical sciences, with numerous precedents for improving drug targeting and absorption
Source Patent Element
Treatment method for hematological malignancies with tyrosine kinase inhibitors
PTD Variation
Implementing blockchain-based secure patient data management
Obviousness Reasoning
Secure digital health record management is a standard solution in healthcare technology, representing an obvious technological integration
Source Patent Element
Combination treatment strategies for FLT3 mutated cancers
PTD Variation
Using IoT-based real-time patient monitoring to track treatment efficacy
Obviousness Reasoning
Remote patient monitoring is a predictable technological evolution in personalized medicine, applying standard IoT technologies to medical treatment tracking
Source Patent Element
Genetic testing for FLT3 mutations prior to treatment
PTD Variation
Implementing next-generation sequencing with deep learning mutation prediction
Obviousness Reasoning
Advanced genomic analysis using machine learning represents a natural progression in precision oncology diagnostic technologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857546 and the disclosed technological variations, a person of ordinary skill in the art would find the proposed system of FLT3 cancer treatment using crenolanib with integrated digital technologies to be an obvious combination of known techniques in personalized medicine, rendering potential patent claims in this domain anticipated and non-patentable under standard obviousness analysis.

Original Patent Information

Patent NumberUS 11,857,546
TitleCrenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment
Assignee(s)Arog Pharmaceuticals, Inc.